Yamakawa Naoki, Suzuki Koichiro, Yamashita Yasunobu, Katsu Takashi, Hanaya Kengo, Shoji Mitsuru, Sugai Takeshi, Mizushima Tohru
Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan; Shujitsu University School of Pharmacy, Okayama 703-8516, Japan.
Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan.
Bioorg Med Chem. 2014 Apr 15;22(8):2529-34. doi: 10.1016/j.bmc.2014.02.032. Epub 2014 Mar 12.
Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory effect by inhibiting cyclooxygenase activity. We previously suggested that in addition to cyclooxygenase-inhibition at the gastric mucosa, NSAID-induced gastric mucosal cell death is required for the formation of NSAID-induced gastric lesions in vivo. We showed that celecoxib exhibited the most potent membrane permeabilizing activity among the NSAIDs tested. In contrast, we have found that the NSAID rofecoxib has very weak membrane permeabilizing activity. To understand the membrane permeabilizing activity of coxibs in terms of their structure-activity relationship, we separated the structures of celecoxib and rofecoxib into three parts, synthesized hybrid compounds by substitution of each of the parts, and examined the membrane permeabilizing activities of these hybrids. The results suggest that the sulfonamidophenyl subgroup of celecoxib or the methanesulfonylphenyl subgroup of rofecoxib is important for their potent or weak membrane permeabilizing activity, respectively. These findings provide important information for design and synthesis of new coxibs with lower membrane permeabilizing activity.
非甾体抗炎药(NSAIDs)通过抑制环氧化酶活性来实现其抗炎作用。我们之前提出,除了在胃黏膜处抑制环氧化酶外,NSAID诱导的胃黏膜细胞死亡对于体内NSAID诱导的胃损伤形成也是必需的。我们发现,在测试的NSAIDs中,塞来昔布表现出最强的膜通透活性。相比之下,我们发现NSAID罗非昔布的膜通透活性非常弱。为了从结构-活性关系的角度理解昔布类药物的膜通透活性,我们将塞来昔布和罗非昔布的结构分为三个部分,通过替换每个部分合成了杂合化合物,并检测了这些杂合物的膜通透活性。结果表明,塞来昔布的磺酰胺基苯基亚组或罗非昔布的甲磺酰基苯基亚组分别对其强或弱的膜通透活性很重要。这些发现为设计和合成具有较低膜通透活性的新型昔布类药物提供了重要信息。